JPRN-jRCT2080222177未知3 期
A Phase III, Open-label, 52week Study Evaluating the Safety and Efficacy of KRP-AB1102F DPI in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 40age old 至 ot applicable（—）
- 性别
- All
入选标准
- •COPD patients with post-bronchodilator FEV1 between 30 and 80 % of predicted
排除标准
- •- History or current diagnosis of asthma
- •-Patient hospitalized for an acute COPD exacerbation within 3 months prior to screening visit, and others
研究者
相似试验
进行中（未招募）
1 期
Phase 3 Study Assessing Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit)CTIS2022-501535-16-00Amgen Inc.172
进行中（未招募）
3 期
Phase 3 Study for Immunogenicity and Safety of the 9vHPV Vaccine in Japanese Boys and GirlsJPRN-jRCT2031210080Tanaka Yoshiyuki300
进行中（未招募）
1 期
Phase 3 Study for Immunogenicity and Safety of the 9vHPV Vaccine inJapanese Boys and GirlsPapillomavirus InfectionsMedDRA version: 20.0Level: HLGTClassification code 10047438Term: Viral infectious disordersSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10063001Term: Human papilloma virus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 21.1Level: PTClassification code 10071146Term: Human papilloma virus immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2020-001170-29-Outside-EU/EEAMerck Sharp & Dohme LLC
进行中（未招募）
1 期
A study to assess the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).Cystic FibrosisEUCTR2015-001997-16-GBVertex Pharmaceuticals Incorporated35
进行中（未招募）
1 期
A study to assess the safety, pharmacokinetics, and pharmacodynamics of ivacaftor in children less than 24 months of age with cystic fibrosis (a rare hereditary disease that affects the lungs, digestive system and other organs).Cystic FibrosisEUCTR2015-001997-16-IEVertex Pharmaceuticals Incorporated35